Cited by 166Gut microbiota and healthEscherichia coli research studiesCancer Research and Treatments

Colorectal cancer: the facts in the case of the microbiota

Open access
Clay, Slater L., Fonseca-Pereira, Diogo, Garrett, Wendy S.·2022·Journal of Clinical Investigation

Abstract

The importance of the microbiota in the development of colorectal cancer (CRC) is increasingly evident, but identifying specific microbial features that influence CRC initiation and progression remains a central task for investigators. Studies determining the microbial mechanisms that directly contribute to CRC development or progression are revealing bacterial factors such as toxins that contribute to colorectal carcinogenesis. However, even when investigators have identified bacteria that express toxins, questions remain about the host determinants of a toxin's cancer-potentiating effects. For other cancer-correlating bacteria that lack toxins, the challenge is to define cancer-relevant virulence factors. Herein, we evaluate three CRC-correlating bacteria, colibactin-producing Escherichia coli, enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum, for their virulence features relevant to CRC. We also consider the beneficial bioactivity of gut microbes by highlighting a microbial metabolite that may enhance CRC antitumor immunity. In doing so, we aim to elucidate unique and shared mechanisms underlying the microbiota's contributions to CRC and to accelerate investigation from target validation to CRC therapeutic discovery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci155101

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Fusobacterium nucleatum is often found in colorectal carcinoma tissues and reduces clinical response to chemotherapy.

    “while Fusobacterium nucleatum is often found in colorectal carcinoma tissues and reduces the clinical response to chemotherapy.”

    From Meta-hallmarks of aging and cancer (2023) · cites this paper as [96]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [91]Sanders BE et al FusoPortal: an interactive repository of hybrid MinION-sequenced fusobacterium genomes improves gene identification and characterization mSphere 2018 3 4 e00228-18 29976644 PMC6034081
  2. [103]Borozan I et al Molecular and pathology features of colorectal tumors and patient outcomes are associated with Fusobacterium nucleatum and its subspecies animalis [published online November 4, 2021]. Cancer Epidemiol Biomarkers Prev 10.1158/1055-9965.epi-21-0463 34737207 PMC8755593 · DOI · Paper page
  3. [104]Cochrane K et al A survey of Fusobacterium nucleatum genes modulated by host cell infection Microb Genom 2020 6 2 e000300 31661053 PMC7067209

Cited by

Sorted by citations

Authors
Clay, S. L., Fonseca-Pereira, D., & Garrett, W. S.
Affiliations
  • Harvard University (US)
  • Broad Institute (US)
Corresponding author
Garrett, Wendy S.
Venue
Journal of Clinical Investigation
Published
2022-02-15
Volume
132
Issue
4
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4212788182
Cited by
166
References
124
Citations by year
2026: 33 · 2025: 29 · 2024: 44 · 2023: 46 · 2022: 14
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Research UK (27140, #C10674/A27140, A27140)
  • National Institutes of Health
  • National Cancer Institute (T32CA207021, R01CA154426)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Escherichia coli research studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
Keywords
colorectal cancer, gut microbiota, colibactin, Escherichia coli, enterotoxigenic Bacteroides fragilis, Fusobacterium nucleatum, bacterial toxins, virulence factors, colorectal carcinogenesis, microbial metabolites, antitumor immunity, host-microbe interactions
MeSH terms
Gastrointestinal Microbiome, Animals, Bacteria, Humans, Colorectal Neoplasms, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review